
Home > Clinical Trial Services > Clinical Laboratory Testing


In deep consideration of the above, we, SRL Medisearch, collect the samples from the investigator's sites with full use of the SRL's collection network and alliances
situated in more than 80 locations in Japan.
Also the recent inauguration of SRL's central laboratory exclusive for clinical trials at Sagamihara with a laboratory testing system in compliance with GLP (Good Laboratory Practice) and GCP (Good Clinical Practice) will make more competent the services of SRL Medisearch for clinical trials.
SRL Sagamihara Laboratory functions as “Central Laboratory dedicated to clinical trials”in compliance with the following guidelines.
The College of American Pathologists (CAP), an authoritative external organization that certifies accuracy, has certified the SRL’s main laboratories, including the Hachioji laboratory complex, for compliance with the standards of facility inspection.

(Breast cancer tissue EGFR(HER1))

(Breast cancer tissue HER2/erbB2)
The proteins expressed by coding of the genes are indispensable for the contemporary exploration of molecular targeting drugs. The target genes in the expressed protein of cells or tissue can be localized by immunostaining with a specific antibody.
With our abundant experience in biomarker screening at the drug development stage and phases I through III we can fully support GCP-based clinical trials.
SRL, Inc., as a pioneer in Japan, conducts the testing to evaluate the safety of “drugs of biological origin” and “drugs of specified biological origin” which have become indispensable to the application for drug production licenses due to the amendment of the Pharmaceutical Law in 2005.
This test is designed to evaluate the virus clearance rate in the physical and chemical treatment in the production processes, namely in the thermal, SD, acid, filtering, etc.